CLINICAL_TRIALS
trial_result
· 2021-11-02
Clinical Trial Update: ITI-007 (Lumateperone Tosylate) for Schizophrenia [Phase 2]
Summary
Phase 2 trial of ITI-007 (Lumateperone Tosylate) for schizophrenia has been terminated with results posted in 2021.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: New York State Psychiatric Institute | Conditions: Schizophrenia | Phase 2 | Status: TERMINATED | Results posted: 2021-11-02